NCT07047690View on ClinicalTrials.gov

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 7, 2026

Study Completion Date

October 29, 2027

Conditions
Systemic Sclerosis
Interventions
DRUG

Nemolizumab

Subcutaneous Injection

DRUG

Placebo

Subcutaneous Injection

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY